CN113521155A - Traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows and application thereof - Google Patents
Traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows and application thereof Download PDFInfo
- Publication number
- CN113521155A CN113521155A CN202111054488.2A CN202111054488A CN113521155A CN 113521155 A CN113521155 A CN 113521155A CN 202111054488 A CN202111054488 A CN 202111054488A CN 113521155 A CN113521155 A CN 113521155A
- Authority
- CN
- China
- Prior art keywords
- parts
- sows
- bleeding
- pore
- lacrimation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Abstract
The invention discloses a traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows and application thereof, and belongs to the field of medicines. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-20 parts of baicalin, 5-10 parts of dipsacus asperoides saponin ethyl, 5-10 parts of ferulic acid, 10-20 parts of radix rehmanniae extract, 5-10 parts of astragalus polysaccharide, 10-20 parts of angelica polysaccharide, 5-10 parts of hesperidin and 5-20 parts of oriental wormwood extract. The Chinese medicinal composition can be made into oral liquid, granule, premix, tablet, etc. by conventional process, and can be used for preventing and relieving formation and development of lacrimation and pore hemorrhage of sow, and treating inflammatory reaction caused by excessive ophthalmic inflammatory secretion, capillary permeability change, and various toxins. The preparation method is reliable, the curative effect is exact, the side effect is small, and the use is convenient.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows and application thereof.
Background
With the intensive and large-scale development of the pig raising industry in China, the problems of poor immunity and disease resistance, high morbidity, high mortality and the like of the swinery in China generally exist, and extremely serious economic loss is caused to the national economic development and farmers. The reason is as follows: firstly, the disease-resistant immunity of the pig is reduced due to stress caused by unscientific feeding pipe, severe environment, long-distance transportation, house transfer and the like; secondly, infectious diseases are frequent, in particular immunosuppressive diseases; thirdly, the abuse of chemical drugs for preventing and treating diseases not only causes drug residues to cause food safety problems, but also causes chronic poisoning of organisms and damages to immune tissues and organs; fourthly, after the vaccine is used, the antibody level can not be removed, and the immune and disease prevention effects can not be achieved; fifthly, antibiotics and antiviral drugs are abused to cause bacterial drug resistance and virus variation; and sixthly, mycotoxin poisoning causes damage to liver and kidney of tissue organs, particularly immune organs, so that the immune disease resistance of the pig body is reduced.
The tear spots of the sows are mainly shown by the secretion around the eyes, if the sows are found to have the tear spots of the eye droppings, the sows are not treated in time, after a period of time, pores bleed, ears bleed, and the backs of the sows look dirty. This is because the sow has weakened liver function, which causes symptoms such as bleeding in pores. Sows with these symptoms have low farrowing rate, high return rate, and abortion. The reason for the lacrimation of the sow is complex and mainly comprises the following steps: firstly, due to environmental factors, the air quality is poor, the dust is more, the ammonia gas concentration is higher, the eye conjunctiva is stimulated to cause the formation of tear spots, and even some pigs still have eye flushing; the other is disease factors, such as infectious diseases, lacrimal gland inflammation caused by toxin accumulation, conjunctival inflammation and the like, and secretion is increased to form tear spots. The reasons for pore bleeding of sows mainly include: firstly, the sow caused by viral or blood protozoan diseases such as the blue ear virus and eperythrozoon is infected, and capillary vessels are damaged to cause pore bleeding; secondly, mycotoxins exceed the standard, such as aflatoxin, T2 toxin, stachyosin and the like; and thirdly, skin damage and pruritus caused by the parasites on the body surface, and the sow rubs the handrail. In clinical practice, pore bleeding and lacrimation commonly occur and appear in the same sow, which seriously affects the production performance and health level of the sow and causes a series of problems of no oestrus, no pregnancy, abortion and stillbirth, postpartum inflammation, diarrhea of suckling piglets and the like, so that the prevention and treatment of the pore bleeding and the lacrimation of the sow are in very strong practical need.
At present, the solution methods for the multiple diseases of the sows in China are about the following: the dosage of the vaccine is increased to strengthen immunity, but the vaccine can only be used for preventing diseases, and after immunization, antibodies cannot be removed, so that the immune effect is not ideal; use hyperimmune serum, interferon, etc., but only useful for a certain disease or several diseases, but ineffective for the whole body immunity, and the price is expensive, in fact, it is irretrievable; the effect is not ideal when a large amount of antibiotics, chemical drugs and antiviral drugs are used, not only the food safety problem is caused by drug residues, but also the health and life safety of animals and human beings are harmed; fourthly, in the aspect of mycotoxin poisoning, a mildew remover is mostly used, but only part (about 20-30%) of mycotoxin can be removed, and no effect is caused on tissue and organ damage caused after the mycotoxin is absorbed by an organism; the feeding tube is improved to a certain extent, but the effect is limited, so that the problem of single side can be solved, and the problem of disease resistance and immunity of the whole organism cannot be solved at all. In a word, the prior art only treats headache and foot pain, and lacks a method which can fundamentally solve the problems of overall immunity reduction, more diseases and high mortality rate.
Based on the analysis, a traditional Chinese medicine composition which is an effective prevention and treatment means for sow pore bleeding and lacrimation and does not affect the sow per se is urgently needed in the industry at present.
Disclosure of Invention
The traditional Chinese medicine considers that: liver stores blood, which pertains to wood, governs tendons, opens into eyes, and tears emerge from eyes, and is the body fluid of liver. In pathological conditions, therefore, lesions in the liver often cause abnormal tear secretion. When the liver function is damaged, the number of the lacrimation spots is increased, meanwhile, liver pathological changes are caused by mycotoxin, pathogen infection and the like, the formation of the lacrimation spots is aggravated, and simultaneously, symptoms such as capillary vessel rupture, pore bleeding and the like are caused.
In order to solve the problems, the invention provides a traditional Chinese medicine composition for preventing and treating lacrimation and trichoporesis of sows, which can effectively improve the symptoms of the sows and reduce the multi-organ injury of the sows caused by inflammatory factors.
The invention is realized by the following means:
a traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows comprises:
10-30 parts of baicalin, 5-20 parts of dipsacus asperoides saponin ethyl, 5-20 parts of ferulic acid, 10-30 parts of radix rehmanniae extract, 5-20 parts of astragalus polysaccharide, 10-30 parts of angelica polysaccharide, 5-20 parts of hesperidin and 5-20 parts of oriental wormwood extract.
Further, the traditional Chinese medicine composition for treating the lacrimation and the pore bleeding of the sows comprises the following components:
20 parts of baicalin, 10 parts of dipsacus asperoides saponin ethyl, 10 parts of ferulic acid, 20 parts of a radix rehmanniae extract, 10 parts of astragalus polysaccharide, 15 parts of angelica polysaccharide, 5 parts of hesperidin and 10 parts of an oriental wormwood extract.
A medicine comprises any one of the traditional Chinese medicine compositions for treating lacrimation and pore bleeding of sows.
Further, the dosage form of the medicament comprises various preparation forms with or without pharmaceutical excipients.
Further, the formulation includes an oral formulation.
Further, the oral preparation includes, but is not limited to, oral liquid, granules, premix, and tablet.
The invention also discloses a traditional Chinese medicine composition for treating the lacrimation and pore bleeding of sows according to any one of the medicines, or an application of any one of the medicines in preparation of medicines for treating the lacrimation and pore bleeding of sows.
The invention also discloses a traditional Chinese medicine composition for treating the lacrimation and pore bleeding of sows according to any one of the medicines, or an application of any one of the medicines in preparing medicines for preventing the lacrimation and pore bleeding of sows.
The method for preparing the veterinary drug composition comprises the following steps:
the invention has the beneficial effects that:
1. the traditional Chinese medicine composition can effectively solve the problems of low auxiliary prevention and treatment effect of traditional mildew removing agents and vitamins, poor effect of anti-inflammatory treatment of lacrimation formation and pore bleeding of sows by corticosteroids, even side effects of abortion and the like, can effectively treat and prevent symptoms of lacrimation formation and pore bleeding of sows, can improve liver functions, has anti-inflammatory, antioxidant and anti-stress effects, reduces sow abortion, avoids side effects of abortion and the like caused by western anti-inflammatory medicines, and has a good clinical application prospect.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the present invention, parts are calculated as 100 parts by weight relative to the weight of the composition, unless otherwise specified.
All the extracts used in the present invention were purchased from Guanghan Sanxingdui Biotechnology Co., Ltd, baicalin (content 98.5%, batch No. 20180701), radix rehmanniae extract (batch No. 20180608), Dipsacaceae saponin B (content 95.6%, batch No. 20180506), ferulic acid (content 96.5%, batch No. 20180302), Astragalus polysaccharides (content 88.5%, batch No. 20180306), Angelica polysaccharides (content 86.5%, batch No. 20180602), hesperidin (content 87.6%, batch No. 20180401), and Artemisia capillaris extract (batch No. 20180303).
Example 1
A traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows comprises:
10 parts of baicalin, 10 parts of a radix rehmanniae extract, 15 parts of dipsacus asperoides saponin ethyl, 10 parts of ferulic acid, 20 parts of astragalus polysaccharide, 10 parts of angelica polysaccharide, 10 parts of hesperidin and 15 parts of an artemisia capillaris extract.
Example 2
A traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows comprises:
20 parts of baicalin, 10 parts of radix rehmanniae extract, 10 parts of dipsacus asperoides saponin ethyl, 5 parts of ferulic acid, 20 parts of astragalus polysaccharide, 15 parts of angelica polysaccharide, 10 parts of hesperidin and 10 parts of oriental wormwood extract.
Example 3
A traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows comprises:
20 parts of baicalin, 20 parts of radix rehmanniae extract, 5 parts of dipsacus asperoides saponin ethyl, 10 parts of ferulic acid, 10 parts of astragalus polysaccharide, 20 parts of angelica polysaccharide, 5 parts of hesperidin and 10 parts of oriental wormwood extract.
Example 4
A method of preparing the Chinese medicinal composition granules of examples 1-3, comprising:
the traditional Chinese medicine components in the embodiments 1-3 are respectively weighed, 40% of auxiliary materials are respectively added to prepare granules. Taking example 3 as an example:
weighing 20g of baicalin, 20g of radix rehmanniae extract, 5g of dipsacoside, 10g of ferulic acid, 10g of astragalus polysaccharide, 20g of angelica polysaccharide, 5g of hesperidin and 10g of oriental wormwood extract for later use;
weighing 50g of auxiliary materials, wherein the auxiliary materials comprise 25g of glucose, 0.5g of aspartame, 15g of water-soluble starch, 5g of dextrin, 0.5g of microcrystalline cellulose and 4g of beta-cyclodextrin;
mixing 100 parts of the Chinese medicinal composition and 50 parts of auxiliary materials uniformly, spraying purified water, stirring, granulating, drying at 60 +/-5 ℃ under reduced pressure, and finishing granules.
The granules were prepared in the same manner as in example 1 and example 2. The traditional Chinese medicine accounts for 60 percent of the granule
Example 5
A method of preparing the oral liquid of the Chinese medicinal composition of examples 1 to 3, comprising:
the Chinese medicinal components in the embodiments 1 to 3 are respectively weighed and respectively added into purified water to prepare oral liquid. Taking example 3 as an example:
weighing 20g of baicalin, 20g of radix rehmanniae extract, 5g of dipsacoside, 10g of ferulic acid, 10g of astragalus polysaccharide, 20g of angelica polysaccharide, 5g of hesperidin and 10g of oriental wormwood extract for later use;
adding into about 300mL of boiled purified water, adjusting water amount to make the concentration of Chinese medicinal materials 30%, adding 0.5g saccharin for flavoring, bottling in 500mL glass bottle, and autoclaving at 115 deg.C for 15 min.
Proved by verification, the traditional Chinese medicine composition or/and the medicine in the embodiment have the effects of improving and preventing the tear spots and pore bleeding of the sows. The relevant test data are now reported as follows:
test example 1
Observation of effect of the traditional Chinese medicine composition for preventing lacrimation and hair hole bleeding of sows
1.1 test subjects
322 sows in 3 large-scale pig farms of Sichuan Leyu and Jianyang Liangdi are selected as observation targets at random, wherein 58 sows in a control group (without any treatment), 78 sows in a chemical drug group, 56 sows in the group in example 1 (using the Chinese medicinal composition granules prepared in example 1), 64 sows in the group in example 2 (using the Chinese medicinal composition granules prepared in example 2), and 66 sows in the group in example 3 (using the Chinese medicinal composition granules prepared in example 3) are selected as observation targets.
1.2 test methods
The traditional Chinese medicine groups are administrated according to 2000 g/ton of mixed feed, and the chemical medicine groups are continuously administrated for 14 days by adding 100g of vitamin C, 500g of montmorillonite and 100g of doxycycline into each ton of feed. The number of sows with black backs due to tear spots and pore bleeding of sows is respectively observed and counted, and the blood sampling detection is carried out on the total antioxidant capacity (TAOC), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), Malondialdehyde (MDA), inflammatory factors interleukin 2(IL-2), interleukin 6(IL-6) and tumor necrosis factor (TNF-alpha). The conditions of lacrimation, profuse eye droppings, skin pore bleeding of the back and the hip, even back pore blackening due to bleeding and abortion of the sows are recorded, and the whole process from mating to 21 days after delivery is observed.
1.3 test results
The results are shown in tables 1 to 3 below:
TABLE 1 number and proportion of the sows that developed tear spots, bleeding pores and abortion
According to the results in the table 1, the control group sows have the tear spot incidence rate of 72.41%, the pore bleeding incidence rate of 62.07%, the chemical group sows have the tear spot incidence rate of 79.48% and the pore bleeding rate of 87.18% without any treatment within 21 days after mating and delivery, and the difference between the two groups is not obvious; the incidence rate of the tear spots and the hair hole bleeding rate of the sows in the three traditional Chinese medicine embodiment groups are respectively 12.12-21.43% and 6.06-23.21%, and the three traditional Chinese medicine embodiment groups are extremely obviously lower than those of the control group and the chemical drug group, and have obvious effects of preventing the tear spots and the hair hole bleeding of the sows. The Chinese medicine sow has significantly lower abortion rate than the control group and the chemical group, and has a certain effect of preventing abortion. Overall effect example 3 is superior to 1 and 2.
TABLE 2 Oxidation resistance index of each group of sows
The results in table 2 show that the groups of examples 1 to 3 are significantly superior to the control group and the herbal group in each antioxidant index. The embodiment of the traditional Chinese medicine has obvious antioxidant effect.
TABLE 3 immunoinflammatory factor indices for various groups of sows
As can be seen from the results in Table 3, the groups of examples 1 to 3 had significantly lower levels of the blood inflammatory factors IL-2, IL-6 and TNF- α in sows than those of the control group and the group of the chemotherapy group, and had an anti-inflammatory effect.
Test example 2
Observation of effect of traditional Chinese medicine composition for treating lacrimation and hair hole bleeding of sows
1.1 test subjects
180 sows with hair hole bleeding and tear spots are selected from a certain pig farm to be tested, and are divided into a control group, a chemical drug group and examples 1-3 groups, wherein 36 sows are selected from each group.
1.2 test methods
The control group is not treated, and the chemical drug group is added with 100g of vitamin C, 500g of montmorillonite and 100g of doxycycline per ton of feed and continuously administrated for 7 days; the feed of the traditional Chinese medicine embodiment is added into the feed according to 2000 g/ton, and the feed is stirred and administered for 7 days continuously. The extent, recovery time, etc. of tear spots and follicular bleeding were recorded.
The judgment standard of the treatment effect of the tear spots is as follows:
before treatment, all sows have black or red tear spots around orbit, and the unilateral area is more than 2cm2；
After treatment, the unilateral area of the black tear spots around the orbit of the sow is not obviously reduced or improved, and the sow is judged to be invalid;
after treatment, the unilateral area of tear spots around the eye socket of the sow is less than 2cm2Greater than 0.5cm2Judging to be effective;
after treatment, gray tear spots are formed around the orbit of the sow, or black tear spots are in a dot shape and a linear shape, and no obvious spot or tear spot exists, and the effect is judged to be obvious.
The judgment standard of the treatment effect of pore bleeding is as follows:
the neck and back subcutaneous pore bleeding of all sows before treatment is obvious, the range is wide, and the sows have black back characteristics;
after treatment, the bleeding of subcutaneous pores on the neck and back of the sow is obvious, the distribution is wide, the sow is in planar distribution, and the sow is judged to be ineffective;
after treatment, subcutaneous pore bleeding exists on the back of the neck of the sow, and the subcutaneous pore bleeding is distributed in a punctiform or local manner and is judged to be effective;
after treatment, no obvious subcutaneous pore bleeding exists on the neck and the back of the sow, and the effect is judged to be obvious.
1.3 test results
The results are shown in Table 4:
TABLE 4 Effect of improving lacrimation and follicular hemorrhage before and after administration of each group of sows
| Group of | Show effect% | Effective% | Not effective% | The total effective rate% | Abortion% |
| Control group | 0.00 | 22.22 | 77.78 | 22.22 | 13.89 |
| Example 1 | 30.56 | 47.22 | 22.22 | 77.78 | 5.56 |
| Example 2 | 38.89 | 47.22 | 13.89 | 86.11 | 2.78 |
| Example 3 | 44.44 | 50.00 | 5.56 | 94.44 | 0.00 |
| Medicine group | 5.56 | 25.00 | 69.44 | 30.56 | 16.67 |
As can be seen from the results in Table 4, the groups of examples 1 to 3 had extremely significant effects on the treatment of lacrimation and hair hole bleeding in sows.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (8)
1. A traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows comprises:
10-30 parts of baicalin, 5-20 parts of dipsacus asperoides saponin ethyl, 5-20 parts of ferulic acid, 10-30 parts of radix rehmanniae extract, 5-20 parts of astragalus polysaccharide, 10-30 parts of angelica polysaccharide, 5-20 parts of hesperidin and 5-20 parts of oriental wormwood extract.
2. The traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows as claimed in claim 1, comprising:
20 parts of baicalin, 10 parts of dipsacus asperoides saponin ethyl, 10 parts of ferulic acid, 20 parts of a radix rehmanniae extract, 10 parts of astragalus polysaccharide, 15 parts of angelica polysaccharide, 5 parts of hesperidin and 10 parts of an oriental wormwood extract.
3. A medicament comprising the Chinese medicinal composition for treating lacrimation and pore bleeding of sows as claimed in claim 1 or 2.
4. The medicament of claim 3, wherein:
the dosage form of the medicament comprises various preparation forms with or without pharmaceutic adjuvants.
5. The medicament of claim 4, wherein:
the formulation includes an oral formulation.
6. The medicament of claim 5, wherein:
the oral preparation includes but is not limited to oral liquid, granules, premix and tablet.
7. Use of the traditional Chinese medicine composition according to claim 1 or 2 or any one of the medicines according to claims 3-6 in preparation of medicines for treating lacrimation and pore bleeding of sows.
8. Use of the traditional Chinese medicine composition according to claim 1 or 2 or the medicine according to any one of claims 3-6 in preparation of medicines for preventing lacrimation and pore bleeding of sows.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111054488.2A CN113521155A (en) | 2021-09-09 | 2021-09-09 | Traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111054488.2A CN113521155A (en) | 2021-09-09 | 2021-09-09 | Traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113521155A true CN113521155A (en) | 2021-10-22 |
Family
ID=78093110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111054488.2A Pending CN113521155A (en) | 2021-09-09 | 2021-09-09 | Traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113521155A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623063A (en) * | 2015-02-13 | 2015-05-20 | 成都市飞龙水处理技术研究所青白江第一分所 | Decoction medicine for treating blepharitis ciliaris and preparation method thereof |
| CN105012673A (en) * | 2015-07-29 | 2015-11-04 | 尹华江 | Traditional Chinese medicine for preventing and treating mycotoxicosis of domestic animals and preparation method of traditional Chinese medicine |
| CN112641794A (en) * | 2020-12-09 | 2021-04-13 | 湖南中医药大学 | Application of dipsacus asperoides saponin B in preparation of medicine for preventing and treating vascular diseases |
-
2021
- 2021-09-09 CN CN202111054488.2A patent/CN113521155A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623063A (en) * | 2015-02-13 | 2015-05-20 | 成都市飞龙水处理技术研究所青白江第一分所 | Decoction medicine for treating blepharitis ciliaris and preparation method thereof |
| CN105012673A (en) * | 2015-07-29 | 2015-11-04 | 尹华江 | Traditional Chinese medicine for preventing and treating mycotoxicosis of domestic animals and preparation method of traditional Chinese medicine |
| CN112641794A (en) * | 2020-12-09 | 2021-04-13 | 湖南中医药大学 | Application of dipsacus asperoides saponin B in preparation of medicine for preventing and treating vascular diseases |
Non-Patent Citations (8)
| Title |
|---|
| 史丽萍 等: "《甘肃中医药产业发展的思考与探索》", 31 January 2019, 甘肃科学技术出版社 * |
| 张泉鑫 等: "《猪病》", 30 June 2007, 中国农业出版社 * |
| 杨果平: "泪斑痕迹对母猪健康的影响", 《浙江畜牧兽医》 * |
| 杨秀伟: "《中药成分的吸收、分布、代谢、排泄、毒性与药效 上册》", 30 August 2006, 中国医药科技出版社 * |
| 柴瑞震: "《肝脏疾病吃什么？禁什么？》", 31 July 2014, 黑龙江科学技术出版社 * |
| 王怀禹: "猪泪斑产生的原因与防治", 《猪业科学》 * |
| 田燕 等: "《一味中药通便灵》", 31 January 2018, 河南科学技术出版社 * |
| 钟正灵 等: "阿魏酸对急性肝损伤的保护作用", 《中国临床药理学与治疗学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103800661A (en) | Composition for improving immunity and relieving physical fatigue and preparation thereof | |
| CN103372189B (en) | Compound traditional Chinese medicine extract preparation for preventing and treating proventriculitis of chicken and preparation method thereof | |
| CN105168807B (en) | The Chinese medicine composition and preparation method thereof for treating pig blue-ear disease | |
| CN108096443B (en) | Medicine for eliminating toxins in livestock and poultry and improving immunity of organism, preparation method and application thereof | |
| CN113521155A (en) | Traditional Chinese medicine composition for treating lacrimation and pore bleeding of sows and application thereof | |
| CN109999117A (en) | Prevent and treat enteritis, bacillary dysentery, dysentery, intractable diarrhea Chinese medicine composition | |
| CN105381300A (en) | Traditional Chinese medicinal preparation for preventing and treating swine fever | |
| CN110812389B (en) | Soluble granule for improving pig immunity and preparation method thereof | |
| CN105641260A (en) | Traditional Chinese medicinal composition for treating piglet edema disease and preparation method of traditional Chinese medicinal composition | |
| CN107998332B (en) | Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof | |
| CN113080450A (en) | Health food for inhibiting and killing helicobacter pylori and preparation method thereof | |
| CN101698068A (en) | Medicine for treating high-pathogenicity porcine reproductive and respiratory syndrome | |
| CN106581172B (en) | Medicine for preventing and treating mycotic vaginitis, trichomonas vaginitis and senile vaginitis and preparation method thereof | |
| CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN110478429B (en) | Traditional Chinese medicine composition for treating zearalenone poisoning of livestock and preparation method thereof | |
| CN116942745B (en) | Traditional Chinese medicine composition for treating salpingitis of laying hens and preparation method thereof | |
| CN111588773B (en) | Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof | |
| CN115006488B (en) | Pharmaceutical composition for preventing and treating proventriculitis and myogastritis of poultry and preparation method and application thereof | |
| CN107582650A (en) | A kind of Chinese medicine composition for being used to prevent and treat sow mastitis | |
| CN101279029B (en) | Liquid oral vaccine for curing blue-ear pig disease and method of preparing the same | |
| CN115006353A (en) | A nanometer sustained release preparation of fibrauretine extract with low adverse side effect, and its preparation method | |
| CN105168787B (en) | Chinese medicine composition and preparation method thereof for improving pig immunity | |
| CN107223960A (en) | It is a kind of that there is composition of improvement prostate gland symptoms and preparation method thereof | |
| CN104689295A (en) | Medicine for treating mycoplasma type colpitis | |
| CN111317767A (en) | Solanum torvum fruit composition for damp-heat syndrome and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211022 |
|
| RJ01 | Rejection of invention patent application after publication |